Clinical trial · Interventional
Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract
A Phase II Monocentric Study of Oxaliplatin in Combination With Gemcitabine in Patients With Advanced/Metastatic Transitional Cell Carcinoma of the Urothelial Tract
NCT00127595CI-TRIAL-00000105terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase II monocentric study of oxaliplatin (Ox) in combination with gemcitabine (Gem; GEMOX) in patients (pts) with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Transitional Cell | Transitional Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gemcitabine, oxaliplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- response rate (Response Evaluation Criteria in Solid Tumors [RECIST] criteria)
Secondary outcomes (3)
- measure
- overall survival
- measure
- disease free survival
- measure
- toxicity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Transitional cell carcinoma * Histologically-proven * Locally advanced unresectable or metastatic * With at least one measurable target * Informed consent signed Exclusion Criteria: * Previous chemotherapy * Previous radiotherapy * Performance status \>=2 * Peripheral neuropathy \>=1
References
Publications (0)
Data not yet available
No reference posted for this study.